PL2205720T3 - Kompozycja do leczenia stwardnienia rozsianego - Google Patents

Kompozycja do leczenia stwardnienia rozsianego

Info

Publication number
PL2205720T3
PL2205720T3 PL08838676T PL08838676T PL2205720T3 PL 2205720 T3 PL2205720 T3 PL 2205720T3 PL 08838676 T PL08838676 T PL 08838676T PL 08838676 T PL08838676 T PL 08838676T PL 2205720 T3 PL2205720 T3 PL 2205720T3
Authority
PL
Poland
Prior art keywords
treatment
composition
multiple sclerosis
sclerosis
Prior art date
Application number
PL08838676T
Other languages
English (en)
Inventor
Arnaud Foussat
Original Assignee
Txcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/873,623 external-priority patent/US20090104142A1/en
Application filed by Txcell filed Critical Txcell
Publication of PL2205720T3 publication Critical patent/PL2205720T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08838676T 2007-10-17 2008-10-17 Kompozycja do leczenia stwardnienia rozsianego PL2205720T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301475A EP2050814A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
US11/873,623 US20090104142A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
EP08838676.8A EP2205720B1 (en) 2007-10-17 2008-10-17 Compositions for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
PL2205720T3 true PL2205720T3 (pl) 2017-06-30

Family

ID=40089903

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08838676T PL2205720T3 (pl) 2007-10-17 2008-10-17 Kompozycja do leczenia stwardnienia rozsianego

Country Status (18)

Country Link
US (2) US9517253B2 (pl)
EP (2) EP2050814A1 (pl)
JP (2) JP2011500645A (pl)
KR (1) KR20100074286A (pl)
CN (1) CN101842478B (pl)
AU (1) AU2008313694B2 (pl)
CA (1) CA2702634C (pl)
CY (1) CY1118710T1 (pl)
DK (1) DK2205720T3 (pl)
ES (1) ES2618583T3 (pl)
HR (1) HRP20170353T1 (pl)
HU (1) HUE032066T2 (pl)
LT (1) LT2205720T (pl)
PL (1) PL2205720T3 (pl)
PT (1) PT2205720T (pl)
RU (1) RU2492234C2 (pl)
SI (1) SI2205720T1 (pl)
WO (1) WO2009050283A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132697A2 (en) * 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
ES2487465T1 (es) * 2011-05-19 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para la preparación y usos
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
RU2600160C1 (ru) * 2015-08-07 2016-10-20 Юрий Леонидович Шевченко Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний
CN105254765A (zh) * 2015-10-10 2016-01-20 江汉大学 重组蛋白MOG35-55-I-Abβ1-α1及其基因和应用
WO2018078112A1 (en) * 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
WO2018159787A1 (ja) * 2017-03-01 2018-09-07 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2018188730A1 (en) 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
US12227756B2 (en) 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
GB201915359D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
AU2020370033A1 (en) 2019-10-23 2022-06-02 Ucl Business Ltd Engineered regulatory T cell

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008A (en) * 1845-04-22 Improvement w the manufacture of oil from resin
WO1992021367A1 (en) 1991-05-31 1992-12-10 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for immune-related disease
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
WO2002077025A1 (en) 2001-03-23 2002-10-03 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
JP2007509063A (ja) * 2003-10-17 2007-04-12 ベイラー　カレッジ　オブ　メディスン Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法
CA2585462A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
PT1739166E (pt) * 2005-07-01 2011-09-22 Inst Nat Sante Rech Med Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito

Also Published As

Publication number Publication date
CN101842478A (zh) 2010-09-22
PT2205720T (pt) 2017-03-13
WO2009050283A1 (en) 2009-04-23
HUE032066T2 (en) 2017-09-28
HRP20170353T1 (hr) 2017-05-05
US20100221219A1 (en) 2010-09-02
CN101842478B (zh) 2014-04-02
RU2492234C2 (ru) 2013-09-10
EP2205720B1 (en) 2016-12-14
US20170042992A1 (en) 2017-02-16
LT2205720T (lt) 2017-03-27
EP2050814A1 (en) 2009-04-22
US9517253B2 (en) 2016-12-13
RU2010119505A (ru) 2011-11-27
JP2011500645A (ja) 2011-01-06
ES2618583T3 (es) 2017-06-21
EP2205720A1 (en) 2010-07-14
AU2008313694B2 (en) 2015-03-26
KR20100074286A (ko) 2010-07-01
AU2008313694A1 (en) 2009-04-23
CA2702634A1 (en) 2009-04-23
SI2205720T1 (sl) 2017-04-26
DK2205720T3 (en) 2017-03-20
CA2702634C (en) 2017-06-13
JP2014221819A (ja) 2014-11-27
CY1118710T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
LTPA2018014I1 (lt) Farmacinė kompozicija 514
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
LT2478907T (lt) Kompozicijos vėžiui gydyti
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
HUE051206T2 (hu) Módszerek progresszív szklerózis multiplex kezelésére
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
BRPI0913806A2 (pt) "composição"
PT2205720T (pt) Composições para tratamento de esclerose múltipla
BRPI0813775A2 (pt) Composição
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0810557A2 (pt) composição
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
BRPI0811274A2 (pt) Composição
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
BRPI0821249A2 (pt) Composição de endurecimento
PT2182988E (pt) Composição radiofarmacêutica
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0811002A2 (pt) Composição biofertilizante
BRPI0820960A2 (pt) composição